Will Pharma live up to its improved reputation?
Blog Post21 May, 2021
All eyes are on Pharma, BioTech and Life Sciences, with both excitement and apprehension.
Since the pandemic began, the world kept its focus on Pharma, waiting for vaccines and treatments – and watching for indiscretions. Using our proprietary RepTrak model, our Data Science team monitored the Pharma, BioTech and Life Sciences industry throughout 2020 and into 2021 to gauge public perception as companies responded to this urgent call to action.
Pre-pandemic, the public had felt betrayed by medication price hikes and was looking to more holistic approaches outside of traditional medicine. But in 2020, Pharma, BioTech and Life Sciences' reputation made a major positive leap, earning a Strong reputation score of 72.8 — and it's continuing to increase into 2021.
But be forewarned: these high scores are not a permanent stamp of approval, but a call to action to continuously meet this “halo glow” with actions and initiatives moving forward.
We examine the evolution of Pharma reputation in 2020 and Q1 2021, the stateside differences, the effects on one vaccine maker: Johnson & Johnson.
